Establishes an insulin resource center and hotline for uninsured diabetes patients to connect them with resources about diabetes and programs to help them secure insulin.
Will establish an insulin resource center and hotline for uninsured diabetes patients.
Occurrences
Fourteen Senators from each party now cosponsor the Shaheen-led bill to lower insulin costs for Americans with and without insurance.
Evidence
AP reports that a bill introduced by Sens. Jeanne Shaheen, Raphael Warnock, Susan Collins and John Kennedy would cap insulin at $35 per month for private insurance plans and start a pilot program to provide more affordable insulin to uninsured Americans in 10 states. AP also reports the legislation faces hurdles and competing priorities.
Congress.gov lists Sen. Jeanne Shaheen as sponsor of S.1269, the INSULIN Act of 2023. The latest action was referral to the Senate Health, Education, Labor, and Pensions Committee on April 25, 2023, and the tracker status is Introduced. The CRS summary says the bill would cap private insurance insulin cost-sharing beginning in 2025.
Medicare.gov says Medicare covers insulin in different situations and that beneficiaries pay no more than $35 for a one-month supply of each Part B- and Part D-covered insulin product, with no deductible for insulin.
The Senate roll call shows H.R. 5376, as amended, passed 50-50 with the Vice President voting yea. The alphabetical vote list records Shaheen (D-NH) voting Yea.
Congress.gov lists S.3700 as the Affordable Insulin Now Act. Its latest action was referral to the Senate Finance Committee on February 17, 2022, and the status is Introduced. The CRS summary says it would cap cost-sharing for insulin under private health insurance and Medicare Part D.
Teen Vogue reported that the Inflation Reduction Act capped insulin costs for Medicare recipients but did not address wider issues or cover uninsured patients, and that advocates were frustrated by the lack of effective measures for uninsured diabetics.
Assessments
The promised outcome was a specific federal resource center and hotline for uninsured diabetes patients. The evidence shows Shaheen supported and sponsored insulin-affordability legislation, including bills addressing cost-sharing and a proposed uninsured-patient pilot, and voted for the Inflation Reduction Act's Medicare insulin cap. But those actions did not establish a resource center or hotline for uninsured patients, and the cited Shaheen-sponsored bills did not become law. This qualifies as a serious effort without delivery of the promised outcome.